Amneal Pharmaceuticals, Inc. (AMRX)
- Sector
- Pharmaceuticals
- Last price
- $19.57
- As of
Kresmion compiles this page from AMRX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Amneal Pharmaceuticals, Inc. (AMRX): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-10.
See the full AMRX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for AMRX on one page. Preview it with sample data, then open it live with a free account.
Preview the AMRX dossierActive signals for AMRX
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +1949% to AMRX (2026Q2)
- highCONSENSUS_SELL
3 tracked funds reduced AMRX this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 70% of AMRX (2026Q2)
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 68% of AMRX (2026Q2)
- highINSTITUTIONAL_EXIT
D. E. Shaw & Co., Inc. cut 55% of AMRX (2026Q2)
FREE, NO ACCOUNT
Every signal on AMRX, as it fires
You are seeing 5 of 14 signals recorded on AMRX since 2026-05-16.
The five above all landed on 2026-08-16. The other 9 were recorded on 3 other days. 8 of the 14 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in AMRX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 03168L105 · 2026Q2 | $19.4M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 03168L105 · 2026Q2 | $13.4M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 03168L105 · 2026Q2 | $4M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 03168L105 · 2026Q2 | $1.5M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 03168L105 · 2026Q2 | $256K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, AMRX
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
AMRX against its peers
AMRX's operating margin of 13.1% ranks in the 78th percentile of 19 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | AMRX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 3.0B USD | 723M USD | 72 | 22 |
| Gross margin | 36.9% | 51.8% | 31 | 7 |
| Operating margin | 13.1% | 2.6% | 78 | 19 |
| Net margin | 2.4% | 1.0% | 57 | 21 |
| Return on equity | n/a | -3.6% | n/a | 23 |
| P / E | 89.0x | 15.1x | 79 | 11 |
| 1 year | 100.7% | 26.6% | 90 | 25 |
Peers (25): AXSM, CORT, OGN, AMLX, TARS, JAZZ, SUPN, LQDA, VTRS, HRMY, BHC, XERS, TRVI, GPCR, NUVB, ANIP, OCUL, ZTS, PAHC, INVA, PCRX, OMER, NKTR, AMPH, TEVA. Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (AMRX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow AMRX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to AMRX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.